Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

290
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
290
Psychological and Sociocultural Causes of Schizophrenia01:29

Psychological and Sociocultural Causes of Schizophrenia

92
Schizophrenia, a complex psychiatric disorder, has been historically misunderstood. Early psychological theories attributed its origins to childhood trauma and unresponsive parenting. However, contemporary research largely rejects these notions, favoring the vulnerability-stress hypothesis. This model proposes that individuals with a genetic predisposition to schizophrenia may develop the disorder following exposure to significant environmental stressors. Notably, studies on high-risk...
92
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

696
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
696
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

182
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
182
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

287
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
287
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

145
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
145

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Role Functioning in Clinical High Risk for Psychosis: An Open Trial of "InVEST" (Individualised Vocational and Educational Support and Training).

Early intervention in psychiatry·2025
Same author

Clinical High Risk for Psychosis in Sexual and Gender Minority Populations: Considerations for Assessment and Treatment.

Journal of the American Academy of Child and Adolescent Psychiatry·2025
Same author

Prevalence and Clinical Correlates of Suicidal Ideation and Attempts in Individuals at Clinical High Risk for Psychosis.

Early intervention in psychiatry·2024
Same author

Extortion experiences of recent adult immigrants from Latin America: self-reported prevalence, associated costs, and current mental health.

Injury epidemiology·2024
Same author

Overlap of obsessive compulsive and psychosis risk symptoms in a specialized clinic.

Early intervention in psychiatry·2024
Same author

The association between mental health stigma and face emotion recognition in individuals at risk for psychosis.

Stigma and health·2023

Related Experiment Video

Updated: Jul 12, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.7K

Cannabis and Psychosis.

Michelle L West1, Shadi Sharif1

  • 1Department of Psychiatry, University of Colorado School of Medicine, Anschutz Health Sciences Building, 1890 N Revere Court, Mailstop F443, Aurora, CO 80045, USA.

The Psychiatric Clinics of North America
|October 25, 2023
PubMed
Summary

Cannabis use in young people is linked to increased psychosis risk and symptom worsening. More clinical trials are needed to develop effective treatments for co-occurring psychosis and cannabis use.

Keywords:
AdolescentCannabisClinical high riskEarly interventionEarly psychosisFirst-episode psychosisPsychosisYouth

More Related Videos

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

143
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

238

Related Experiment Videos

Last Updated: Jul 12, 2025

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.7K
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

143
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

238

Area of Science:

  • Psychiatry
  • Addiction Medicine
  • Adolescent Health

Background:

  • Cannabis use is increasingly prevalent among young people.
  • Cannabis use is associated with an elevated risk of psychotic symptoms, including attenuated and acute psychosis.
  • Cannabis use may worsen existing psychosis symptoms in at-risk youth and those with psychotic disorders.

Purpose of the Study:

  • To review the complex relationship between psychosis and cannabis use in young individuals.
  • To highlight the potential exacerbating effects of cannabis on psychosis.
  • To identify gaps in clinical research for treating co-occurring psychosis and cannabis use.

Main Methods:

  • Literature review of studies examining psychosis and cannabis use in adolescents and young adults.
  • Analysis of research on the impact of cannabis on subthreshold and acute psychotic symptoms.
  • Examination of current treatment approaches and their limitations.

Main Results:

  • Cannabis use is a significant risk factor for developing psychotic symptoms in youth.
  • Cannabis use can exacerbate symptoms in individuals with pre-existing psychosis risk or disorders.
  • Existing treatment strategies for early psychosis care may need to integrate cannabis use interventions.

Conclusions:

  • The co-occurrence of psychosis and cannabis use in young people presents a complex clinical challenge.
  • There is a critical need for robust clinical trial research to establish evidence-based treatments for this population.
  • Integrating cannabis use assessment and treatment into early psychosis services is a promising direction.